Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Palatin Technologies

DB:PTNA
Snowflake Description

Flawless balance sheet and undervalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PTNA
DB
$94M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Palatin Technologies has significant price volatility in the past 3 months.
PTNA Share Price and Events
7 Day Returns
-1.6%
DB:PTNA
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-64.2%
DB:PTNA
-7.4%
DE Biotechs
-14.2%
DE Market
PTNA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Palatin Technologies (PTNA) -1.6% -19.1% -44% -64.2% 40% -60.3%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • PTNA underperformed the Biotechs industry which returned -7.4% over the past year.
  • PTNA underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
PTNA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Palatin Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Palatin Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Palatin Technologies.

DB:PTNA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PTNA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (0.18%))
1.033
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.03
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.033 * 5.44%)
5.23%

Discounted Cash Flow Calculation for DB:PTNA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Palatin Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:PTNA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.23%)
2020 44.52 Est @ 13.93% 42.30
2021 48.81 Est @ 9.64% 44.07
2022 52.04 Est @ 6.63% 44.66
2023 54.40 Est @ 4.52% 44.36
2024 56.05 Est @ 3.05% 43.44
2025 57.18 Est @ 2.02% 42.11
2026 57.93 Est @ 1.3% 40.54
2027 58.38 Est @ 0.79% 38.83
2028 58.64 Est @ 0.44% 37.06
2029 58.75 Est @ 0.19% 35.28
Present value of next 10 years cash flows $412.00
DB:PTNA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $58.75 × (1 + -0.39%) ÷ (5.23% – -0.39%)
$1,041.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,041.09 ÷ (1 + 5.23%)10
$625.25
DB:PTNA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $412.00 + $625.25
$1,037.25
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,037.25 / 229.24
$4.52
DB:PTNA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PTNA represents 0.86379x of AMEX:PTN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.86379x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 4.52 x 0.86379
€3.91
Value per share (EUR) From above. €3.91
Current discount Discount to share price of €0.36
= -1 x (€0.36 - €3.91) / €3.91
90.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Palatin Technologies is available for.
Intrinsic value
>50%
Share price is €0.36 vs Future cash flow value of €3.91
Current Discount Checks
For Palatin Technologies to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Palatin Technologies's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Palatin Technologies's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Palatin Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Palatin Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PTNA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.17
AMEX:PTN Share Price ** AMEX (2020-04-08) in USD $0.42
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Palatin Technologies.

DB:PTNA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AMEX:PTN Share Price ÷ EPS (both in USD)

= 0.42 ÷ 0.17

2.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palatin Technologies is good value based on earnings compared to the Europe Biotechs industry average.
  • Palatin Technologies is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Palatin Technologies's expected growth come at a high price?
Raw Data
DB:PTNA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 2.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
-6.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

DB:PTNA PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 2.54x ÷ -6.3%

-0.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palatin Technologies earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Palatin Technologies's assets?
Raw Data
DB:PTNA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.40
AMEX:PTN Share Price * AMEX (2020-04-08) in USD $0.42
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:PTNA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AMEX:PTN Share Price ÷ Book Value per Share (both in USD)

= 0.42 ÷ 0.40

1.06x

* Primary Listing of Palatin Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Palatin Technologies is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Palatin Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Palatin Technologies has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Palatin Technologies expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-6.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Palatin Technologies expected to grow at an attractive rate?
  • Palatin Technologies's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Palatin Technologies's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Palatin Technologies's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PTNA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PTNA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts -6.3%
DB:PTNA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts -6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PTNA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PTNA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-06-30 13 -10 1
2023-06-30 20 11 -4 2
2022-06-30 18 11 -6 3
2021-06-30 10 -15 -12 3
2020-06-30 0 41 -19 2
2020-04-08
DB:PTNA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 60 39 37
2019-09-30 60 39 37
2019-06-30 60 -22 36
2019-03-31 21 -4 -5
2018-12-31 30 -8 0
2018-09-30 40 -5 8
2018-06-30 67 2 25
2018-03-31 80 -22 26
2017-12-31 82 29 23
2017-09-30 72 21 10
2017-06-30 45 13 -13
2017-03-31 11 12 -40

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Palatin Technologies's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Palatin Technologies's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PTNA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Palatin Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PTNA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-06-30 -0.04 -0.04 -0.04 1.00
2023-06-30 -0.02 0.03 -0.06 2.00
2022-06-30 -0.03 0.01 -0.06 3.00
2021-06-30 -0.05 -0.02 -0.08 3.00
2020-06-30 -0.08 -0.07 -0.09 3.00
2020-04-08
DB:PTNA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.17
2019-09-30 0.17
2019-06-30 0.17
2019-03-31 -0.02
2018-12-31 0.00
2018-09-30 0.04
2018-06-30 0.12
2018-03-31 0.13
2017-12-31 0.12
2017-09-30 0.06
2017-06-30 -0.07
2017-03-31 -0.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Palatin Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Palatin Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Palatin Technologies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Palatin Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Palatin Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Palatin Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • Palatin Technologies's 1-year earnings growth exceeds its 5-year average (10568.9% vs 52.2%)
  • Palatin Technologies's earnings growth has exceeded the Europe Biotechs industry average in the past year (10568.9% vs 14.9%).
Earnings and Revenue History
Palatin Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Palatin Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PTNA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 60.38 36.75 9.81
2019-09-30 60.36 36.95 9.49
2019-06-30 60.30 35.77 9.70
2019-03-31 20.65 -4.64 9.01
2018-12-31 29.62 0.34 9.60
2018-09-30 40.23 8.42 9.14
2018-06-30 67.13 24.70 8.64
2018-03-31 80.42 26.21 7.90
2017-12-31 82.28 23.38 10.26
2017-09-30 71.67 10.32 9.95
2017-06-30 44.72 -13.33 9.61
2017-03-31 10.82 -40.00 9.50
2016-12-31 -49.14 6.14
2016-09-30 -52.36 6.19
2016-06-30 -51.71 6.18
2016-03-31 0.00 -50.44 5.90
2015-12-31 0.00 -46.90 5.62
2015-09-30 8.02 -30.87 5.69
2015-06-30 12.95 -17.67 5.68
2015-03-31 12.95 -9.90 5.40
2014-12-31 12.95 -2.26 5.47
2014-09-30 4.93 -8.64 5.03
2014-06-30 -13.93 4.96
2014-03-31 0.00 -14.33 5.16 10.53
2013-12-31 0.00 -16.83 5.03 10.53
2013-09-30 0.01 -14.90 5.05 10.53
2013-06-30 0.01 -20.86 5.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Palatin Technologies made outstanding use of shareholders’ funds last year (Return on Equity greater than 40%).
  • Palatin Technologies used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Unable to establish if Palatin Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to insufficient past data.
X
Past performance checks
We assess Palatin Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Palatin Technologies has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Palatin Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Palatin Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Palatin Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Palatin Technologies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Palatin Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Palatin Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Palatin Technologies Company Filings, last reported 3 months ago.

DB:PTNA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 91.37 0.00 91.46
2019-09-30 96.12 0.00 96.70
2019-06-30 100.55 0.33 43.51
2019-03-31 16.07 1.33 19.81
2018-12-31 21.14 2.32 24.66
2018-09-30 25.17 4.81 32.62
2018-06-30 26.96 6.28 38.00
2018-03-31 10.23 8.25 25.74
2017-12-31 9.63 10.21 34.96
2017-09-30 5.98 12.16 39.96
2017-06-30 -5.16 14.11 40.45
2017-03-31 -18.86 16.04 55.43
2016-12-31 -15.96 17.64 13.49
2016-09-30 -21.77 18.56 10.25
2016-06-30 -17.59 19.48 9.38
2016-03-31 -4.70 19.63 23.15
2015-12-31 7.48 19.58 33.37
2015-09-30 20.23 19.53 47.52
2015-06-30 12.20 9.78 27.30
2015-03-31 23.98 9.76 36.73
2014-12-31 32.68 9.73 42.69
2014-09-30 10.80 0.00 17.79
2014-06-30 9.79 0.00 12.18
2014-03-31 13.99 0.00 16.72
2013-12-31 15.26 0.00 18.18
2013-09-30 18.67 0.00 22.34
2013-06-30 22.98 0.00 24.42
  • Palatin Technologies has no debt.
  • Palatin Technologies has no debt compared to 5 years ago when it was 29.9%.
  • Palatin Technologies has no debt, it does not need to be covered by operating cash flow.
  • Palatin Technologies has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Palatin Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Palatin Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Palatin Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Palatin Technologies dividends.
If you bought €2,000 of Palatin Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Palatin Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Palatin Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PTNA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PTNA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-06-30
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Palatin Technologies has not reported any payouts.
  • Unable to verify if Palatin Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Palatin Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Palatin Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Palatin Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Palatin Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Palatin Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Palatin Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carl Spana
COMPENSATION $2,274,411
AGE 57
TENURE AS CEO 19.8 years
CEO Bio

Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief Technical Officer and Executive Vice President of Palatin Technologies Inc. From June 1993 to June 1996, he served as Vice President of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm and of Castle Group Ltd., a medical venture capital firm. At Paramount Capital Investments and at Castle Group, Dr. Spana was responsible for discovering, evaluating and commercializing biotechnologies. Through his work at Paramount Capital Investments and Castle Group, he co-founded and acquired several private biotechnology firms. He served as AVAX Technologies, Inc.'s interim President from August 1995 to June 15, 1996. He served as an Chief Technology Officer and Executive Vice President of Rhomed Incorporated. From July 1991 to June 1993, he served as a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana’s qualifications for our board include his leadership experience, business judgment and industry experience. As a senior executive of Palatin for over nineteen years, he provides in-depth knowledge of Palatin Technologies, Inc. company's drug products under development and the competitive and corporate partnering landscape. Dr. Spana has been a Director of Palatin Technologies Inc. since June 1996 and Curalogic A/S since 2005. He has been a Director of RhoMed Incorporated, a wholly-owned subsidiary of Palatin Technologies Inc. since July 1995. Dr. Spana served as a Director of AVAX Technologies, Inc since September 1995. Dr. Spana received his Ph.D. in Molecular Biology from The Johns Hopkins University and his B.S. in Biochemistry from Rutgers University.

CEO Compensation
  • Carl's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Carl's remuneration is higher than average for companies of similar size in Germany.
Management Team

John K. Prendergast

TITLE
Co-Founder & Non-Executive Chairman
COMPENSATION
$268K
AGE
65

Carl Spana

TITLE
Co-Founder
COMPENSATION
$2M
AGE
57
TENURE
19.8 yrs

Steve Wills

TITLE
CFO, COO
COMPENSATION
$2M
AGE
62
TENURE
22.4 yrs

Burns McClellan

TITLE
Vice President of Investor Relations
Board of Directors Tenure

Average tenure and age of the Palatin Technologies board of directors in years:

11.7
Average Tenure
65.5
Average Age
  • The average tenure for the Palatin Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Carl Spana

TITLE
Co-Founder
COMPENSATION
$2M
AGE
57
TENURE
23.8 yrs

Robert deVeer

TITLE
Independent Director
COMPENSATION
$148K
AGE
73
TENURE
21.4 yrs

John K. Prendergast

TITLE
Co-Founder & Non-Executive Chairman
COMPENSATION
$268K
AGE
65
TENURE
19.8 yrs

Alan Dunton

TITLE
Independent Director
COMPENSATION
$170K
AGE
65
TENURE
8.8 yrs

Raymond Rosen

TITLE
Member of Female Sexual Dysfunction Expert Panel

Michael Perelman

TITLE
Member of Female Sexual Dysfunction Expert Panel

J. Hull

TITLE
Independent Director
COMPENSATION
$141K
AGE
67
TENURE
14.6 yrs

Angela Rossetti

TITLE
Independent Director
COMPENSATION
$138K
AGE
66
TENURE
6.8 yrs

Arlene Morris

TITLE
Independent Director
COMPENSATION
$138K
AGE
67
TENURE
4.8 yrs

Tony Manning

TITLE
Independent Director
COMPENSATION
$131K
AGE
57
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Aug 19 Buy J. Hull Individual 05. Aug 19 05. Aug 19 800 €0.70 €561
05. Aug 19 Buy Stephen Wills Individual 01. Aug 19 01. Aug 19 50,000 €0.78 €39,089
05. Aug 19 Buy Robert deVeer Individual 01. Aug 19 01. Aug 19 22,580 €0.78 €17,551
05. Aug 19 Buy Carl Spana Individual 01. Aug 19 02. Aug 19 50,000 €0.78 €38,820
X
Management checks
We assess Palatin Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Palatin Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.

Details
Name: Palatin Technologies, Inc.
PTNA
Exchange: DB
Founded: 1986
$86,579,523
229,240,596
Website: http://www.palatin.com
Address: Palatin Technologies, Inc.
Cedar Brook Corporate Center,
4B Cedar Brook Drive,
Cranbury,
New Jersey, 08512,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AMEX PTN Common Stock NYSE MKT LLC US USD 28. Oct 1993
DB PTNA Common Stock Deutsche Boerse AG DE EUR 28. Oct 1993
LSE 0KF3 Common Stock London Stock Exchange GB USD 28. Oct 1993
Number of employees
Current staff
Staff numbers
18
Palatin Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:43
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/02/12
Last earnings filing: 2020/02/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.